Loading...
Bandhan BSE Healthcare Index Fund Regular Growth
EquityIndex FundsVery High Risk
Regular
NAV (17-Apr-25)
₹9.550.00%1D
Returns (Since Inception)
0.00%
Rated ★4.3+ on 
Fund Overview
Fund Size
₹17 Cr
Expense Ratio
1.01%
ISIN
INF194KB1IR4
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
22 Oct 2024
About this fund
This fund has been in existence for 5 months and 28 days, having been launched on 22-Oct-24.
As of 17-Apr-25, it has a Net Asset Value (NAV) of ₹9.55, Assets Under Management (AUM) of 17.34 Crores, and an expense ratio of 1.01%.
As of 17-Apr-25, it has a Net Asset Value (NAV) of ₹9.55, Assets Under Management (AUM) of 17.34 Crores, and an expense ratio of 1.01%.
- The fund's asset allocation comprises around 99.89% in equities, 0.00% in debts, and 0.11% in cash & cash equivalents.
- You can start investing in Bandhan BSE Healthcare Index Fund Regular Growth with a SIP of ₹1000 or a Lumpsum investment of ₹1000.
Portfolio Summaryas of 31st March 2025
| Equity | ₹17.33 Cr | 99.89% |
| Others | ₹0.02 Cr | 0.11% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹2.62 Cr | 15.10% |
| Cipla Ltd | Equity | ₹1.14 Cr | 6.57% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹1.13 Cr | 6.53% |
| Divi's Laboratories Ltd | Equity | ₹1.03 Cr | 5.93% |
| Dr Reddy's Laboratories Ltd | Equity | ₹0.97 Cr | 5.62% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹0.93 Cr | 5.37% |
| Lupin Ltd | Equity | ₹0.69 Cr | 3.95% |
| Fortis Healthcare Ltd | Equity | ₹0.51 Cr | 2.93% |
| Torrent Pharmaceuticals Ltd | Equity | ₹0.47 Cr | 2.74% |
| Aurobindo Pharma Ltd | Equity | ₹0.45 Cr | 2.61% |
| Mankind Pharma Ltd | Equity | ₹0.38 Cr | 2.18% |
| Alkem Laboratories Ltd | Equity | ₹0.36 Cr | 2.07% |
| Laurus Labs Ltd | Equity | ₹0.33 Cr | 1.92% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹0.32 Cr | 1.86% |
| Zydus Lifesciences Ltd | Equity | ₹0.31 Cr | 1.80% |
| Ipca Laboratories Ltd | Equity | ₹0.29 Cr | 1.69% |
| Abbott India Ltd | Equity | ₹0.22 Cr | 1.26% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹0.22 Cr | 1.26% |
| Biocon Ltd | Equity | ₹0.21 Cr | 1.22% |
| Suven Pharmaceuticals Ltd | Equity | ₹0.21 Cr | 1.19% |
| Syngene International Ltd | Equity | ₹0.19 Cr | 1.11% |
| Piramal Pharma Ltd | Equity | ₹0.19 Cr | 1.10% |
| Gland Pharma Ltd | Equity | ₹0.18 Cr | 1.01% |
| Wockhardt Ltd | Equity | ₹0.16 Cr | 0.95% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.16 Cr | 0.94% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.16 Cr | 0.94% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.16 Cr | 0.92% |
| Ajanta Pharma Ltd | Equity | ₹0.16 Cr | 0.90% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.15 Cr | 0.88% |
| Neuland Laboratories Limited | Equity | ₹0.14 Cr | 0.84% |
| Global Health Ltd | Equity | ₹0.14 Cr | 0.80% |
| Concord Biotech Ltd | Equity | ₹0.14 Cr | 0.79% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.13 Cr | 0.73% |
| Poly Medicure Ltd | Equity | ₹0.12 Cr | 0.70% |
| Natco Pharma Ltd | Equity | ₹0.1 Cr | 0.58% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.1 Cr | 0.57% |
| Granules India Ltd | Equity | ₹0.1 Cr | 0.57% |
| Jubilant Pharmova Ltd | Equity | ₹0.1 Cr | 0.55% |
| Pfizer Ltd | Equity | ₹0.08 Cr | 0.49% |
| Ami Organics Ltd | Equity | ₹0.08 Cr | 0.48% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹0.08 Cr | 0.48% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹0.08 Cr | 0.48% |
| Triparty Repo Trp_020425 | Cash - Repurchase Agreement | ₹0.08 Cr | 0.46% |
| AstraZeneca Pharma India Ltd | Equity | ₹0.07 Cr | 0.43% |
| Sanofi India Ltd | Equity | ₹0.07 Cr | 0.42% |
| Alembic Pharmaceuticals Ltd | Equity | ₹0.07 Cr | 0.41% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹0.07 Cr | 0.38% |
| Marksans Pharma Ltd | Equity | ₹0.06 Cr | 0.37% |
| Strides Pharma Science Ltd | Equity | ₹0.06 Cr | 0.36% |
| Indegene Ltd | Equity | ₹0.06 Cr | 0.36% |
| Net Current Assets | Cash | ₹-0.06 Cr | 0.35% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹0.06 Cr | 0.35% |
| Caplin Point Laboratories Ltd | Equity | ₹0.06 Cr | 0.33% |
| Metropolis Healthcare Ltd | Equity | ₹0.06 Cr | 0.33% |
| Procter & Gamble Health Ltd | Equity | ₹0.06 Cr | 0.33% |
| Aarti Pharmalabs Ltd | Equity | ₹0.05 Cr | 0.30% |
| Sai Life Sciences Ltd | Equity | ₹0.05 Cr | 0.29% |
| Shilpa Medicare Ltd | Equity | ₹0.05 Cr | 0.29% |
| Alivus Life Sciences Ltd | Equity | ₹0.05 Cr | 0.27% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹0.03 Cr | 0.19% |
| HealthCare Global Enterprises Ltd | Equity | ₹0.03 Cr | 0.18% |
| Blue Jet Healthcare Ltd | Equity | ₹0.03 Cr | 0.17% |
| Emcure Pharmaceuticals Ltd | Equity | ₹0.03 Cr | 0.16% |
| FDC Ltd | Equity | ₹0.03 Cr | 0.16% |
| Supriya Lifescience Ltd | Equity | ₹0.03 Cr | 0.15% |
| Indraprastha Medical Corp Ltd | Equity | ₹0.02 Cr | 0.14% |
| Morepen Laboratories Ltd | Equity | ₹0.02 Cr | 0.14% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.02 Cr | 0.13% |
| Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.02 Cr | 0.13% |
| Sequent Scientific Ltd | Equity | ₹0.02 Cr | 0.12% |
| Hikal Ltd | Equity | ₹0.02 Cr | 0.12% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹0.02 Cr | 0.12% |
| Krsnaa Diagnostics Ltd | Equity | ₹0.02 Cr | 0.11% |
| Unichem Laboratories Ltd | Equity | ₹0.02 Cr | 0.11% |
| Dishman Carbogen Amics Ltd | Equity | ₹0.02 Cr | 0.11% |
| Innova Captab Ltd | Equity | ₹0.02 Cr | 0.11% |
| Advanced Enzyme Technologies Ltd | Equity | ₹0.02 Cr | 0.11% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.10% |
| Aarti Drugs Ltd | Equity | ₹0.02 Cr | 0.10% |
| Orchid Pharma Ltd | Equity | ₹0.02 Cr | 0.10% |
| Thyrocare Technologies Ltd | Equity | ₹0.01 Cr | 0.08% |
| RPG Life Sciences Ltd | Equity | ₹0.01 Cr | 0.08% |
| Gufic Biosciences Ltd | Equity | ₹0.01 Cr | 0.07% |
| Gujarat Themis Biosyn Ltd | Equity | ₹0.01 Cr | 0.07% |
| Indoco Remedies Ltd | Equity | ₹0.01 Cr | 0.07% |
| Windlas Biotech Ltd | Equity | ₹0.01 Cr | 0.07% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.01 Cr | 0.06% |
| Bliss GVS Pharma Ltd | Equity | ₹0.01 Cr | 0.06% |
| Syncom Formulation (India) Ltd | Equity | ₹0.01 Cr | 0.06% |
| Vimta Labs Ltd | Equity | ₹0.01 Cr | 0.06% |
| Suven Life Sciences Ltd | Equity | ₹0.01 Cr | 0.06% |
| IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.06% |
| Sigachi Industries Ltd | Equity | ₹0.01 Cr | 0.05% |
| SMS Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.05% |
| Shalby Ltd | Equity | ₹0.01 Cr | 0.04% |
| Lincoln Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.04% |
| Novartis India Ltd | Equity | ₹0.01 Cr | 0.04% |
| Hester Biosciences Ltd | Equity | ₹0.01 Cr | 0.04% |
| Kopran Ltd | Equity | ₹0.01 Cr | 0.04% |
| Tarsons Products Ltd | Equity | ₹0.01 Cr | 0.04% |
| Senores Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.04% |
| Themis Medicare Ltd | Equity | ₹0.01 Cr | 0.03% |
| GPT Healthcare Ltd | Equity | ₹0.01 Cr | 0.03% |
| Suraksha Diagnostic Ltd | Equity | ₹0 Cr | 0.03% |
| KMC Speciality Hospitals (India) Ltd | Equity | ₹0 Cr | 0.02% |
| Sastasundar Ventures Ltd | Equity | ₹0 Cr | 0.02% |
| NGL Fine-Chem Ltd | Equity | ₹0 Cr | 0.02% |
| Cash Margin - Ccil | Cash - Repurchase Agreement | ₹0 Cr | 0.00% |
Allocation By Market Cap (Equity)
Large Cap Stocks
45.26%
Mid Cap Stocks
27.87%
Small Cap Stocks
26.00%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹17.08 Cr | 98.46% |
| Basic Materials | ₹0.1 Cr | 0.59% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
AJ
Abhishek Jain
Since March 2025
Additional Scheme Detailsas of 31st March 2025
ISIN INF194KB1IR4 | Expense Ratio 1.01% | Exit Load No Charges | Fund Size ₹17 Cr | Age 5 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| SBI BSE PSU Bank Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹8.42 Cr | - |
| SBI BSE PSU Bank Index Fund Regular Growth Very High Risk | 0.8% | 0.0% | ₹8.42 Cr | - |
| SBI BSE PSU Bank ETF Very High Risk | 0.3% | - | ₹205.39 Cr | - |
| Tata BSE Quality Index Fund Direct Growth Very High Risk | - | 0.0% | - | - |
| Tata BSE Quality Index Fund Regular Growth Very High Risk | - | 0.0% | - | - |
| HDFC Nifty Top 20 Equal Weight Index Fund Direct Growth Very High Risk | - | 0.0% | ₹70.51 Cr | - |
| HDFC Nifty Top 20 Equal Weight Index Fund Regular Growth Very High Risk | - | 0.0% | ₹70.51 Cr | - |
| Kotak Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.3% | 0.0% | ₹7.20 Cr | - |
| Kotak Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹7.20 Cr | - |
| Mirae Asset BSE 200 Equal Weight ETF Very High Risk | - | - | ₹14.21 Cr | - |
Risk Level
Your principal amount will be at Very High Risk
Take control of your wealth
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Bandhan BSE Healthcare Index Fund Regular Growth?
The NAV of Bandhan BSE Healthcare Index Fund Regular Growth, as of 17-Apr-2025, is ₹9.55.
What is the portfolio composition of Bandhan BSE Healthcare Index Fund Regular Growth?
The fund's allocation of assets is distributed as 99.89% in equities, 0.00% in bonds, and 0.11% in cash and cash equivalents.
Who manages the Bandhan BSE Healthcare Index Fund Regular Growth?
The fund managers responsible for Bandhan BSE Healthcare Index Fund Regular Growth are:-
- Abhishek Jain
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.
Bandhan BSE Healthcare Index Fund Regular Growth
EquityIndex FundsVery High Risk
Regular
NAV (17-Apr-25)
₹9.550.00%1D
Returns (Since Inception)
0.00%
Rated ★4.3+ on
Fund Overview
Fund Size
₹17 Cr
Expense Ratio
1.01%
ISIN
INF194KB1IR4
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
22 Oct 2024
Risk Level
Your principal amount will be at Very High Risk
About this fund
This fund has been in existence for 5 months and 28 days, having been launched on 22-Oct-24.
As of 17-Apr-25, it has a Net Asset Value (NAV) of ₹9.55, Assets Under Management (AUM) of 17.34 Crores, and an expense ratio of 1.01%.
As of 17-Apr-25, it has a Net Asset Value (NAV) of ₹9.55, Assets Under Management (AUM) of 17.34 Crores, and an expense ratio of 1.01%.
- The fund's asset allocation comprises around 99.89% in equities, 0.00% in debts, and 0.11% in cash & cash equivalents.
- You can start investing in Bandhan BSE Healthcare Index Fund Regular Growth with a SIP of ₹1000 or a Lumpsum investment of ₹1000.
Portfolio Summaryas of 31st March 2025
| Equity | ₹17.33 Cr | 99.89% |
| Others | ₹0.02 Cr | 0.11% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹2.62 Cr | 15.10% |
| Cipla Ltd | Equity | ₹1.14 Cr | 6.57% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹1.13 Cr | 6.53% |
| Divi's Laboratories Ltd | Equity | ₹1.03 Cr | 5.93% |
| Dr Reddy's Laboratories Ltd | Equity | ₹0.97 Cr | 5.62% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹0.93 Cr | 5.37% |
| Lupin Ltd | Equity | ₹0.69 Cr | 3.95% |
| Fortis Healthcare Ltd | Equity | ₹0.51 Cr | 2.93% |
| Torrent Pharmaceuticals Ltd | Equity | ₹0.47 Cr | 2.74% |
| Aurobindo Pharma Ltd | Equity | ₹0.45 Cr | 2.61% |
| Mankind Pharma Ltd | Equity | ₹0.38 Cr | 2.18% |
| Alkem Laboratories Ltd | Equity | ₹0.36 Cr | 2.07% |
| Laurus Labs Ltd | Equity | ₹0.33 Cr | 1.92% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹0.32 Cr | 1.86% |
| Zydus Lifesciences Ltd | Equity | ₹0.31 Cr | 1.80% |
| Ipca Laboratories Ltd | Equity | ₹0.29 Cr | 1.69% |
| Abbott India Ltd | Equity | ₹0.22 Cr | 1.26% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹0.22 Cr | 1.26% |
| Biocon Ltd | Equity | ₹0.21 Cr | 1.22% |
| Suven Pharmaceuticals Ltd | Equity | ₹0.21 Cr | 1.19% |
| Syngene International Ltd | Equity | ₹0.19 Cr | 1.11% |
| Piramal Pharma Ltd | Equity | ₹0.19 Cr | 1.10% |
| Gland Pharma Ltd | Equity | ₹0.18 Cr | 1.01% |
| Wockhardt Ltd | Equity | ₹0.16 Cr | 0.95% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.16 Cr | 0.94% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.16 Cr | 0.94% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.16 Cr | 0.92% |
| Ajanta Pharma Ltd | Equity | ₹0.16 Cr | 0.90% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.15 Cr | 0.88% |
| Neuland Laboratories Limited | Equity | ₹0.14 Cr | 0.84% |
| Global Health Ltd | Equity | ₹0.14 Cr | 0.80% |
| Concord Biotech Ltd | Equity | ₹0.14 Cr | 0.79% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.13 Cr | 0.73% |
| Poly Medicure Ltd | Equity | ₹0.12 Cr | 0.70% |
| Natco Pharma Ltd | Equity | ₹0.1 Cr | 0.58% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.1 Cr | 0.57% |
| Granules India Ltd | Equity | ₹0.1 Cr | 0.57% |
| Jubilant Pharmova Ltd | Equity | ₹0.1 Cr | 0.55% |
| Pfizer Ltd | Equity | ₹0.08 Cr | 0.49% |
| Ami Organics Ltd | Equity | ₹0.08 Cr | 0.48% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹0.08 Cr | 0.48% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹0.08 Cr | 0.48% |
| Triparty Repo Trp_020425 | Cash - Repurchase Agreement | ₹0.08 Cr | 0.46% |
| AstraZeneca Pharma India Ltd | Equity | ₹0.07 Cr | 0.43% |
| Sanofi India Ltd | Equity | ₹0.07 Cr | 0.42% |
| Alembic Pharmaceuticals Ltd | Equity | ₹0.07 Cr | 0.41% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹0.07 Cr | 0.38% |
| Marksans Pharma Ltd | Equity | ₹0.06 Cr | 0.37% |
| Strides Pharma Science Ltd | Equity | ₹0.06 Cr | 0.36% |
| Indegene Ltd | Equity | ₹0.06 Cr | 0.36% |
| Net Current Assets | Cash | ₹-0.06 Cr | 0.35% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹0.06 Cr | 0.35% |
| Caplin Point Laboratories Ltd | Equity | ₹0.06 Cr | 0.33% |
| Metropolis Healthcare Ltd | Equity | ₹0.06 Cr | 0.33% |
| Procter & Gamble Health Ltd | Equity | ₹0.06 Cr | 0.33% |
| Aarti Pharmalabs Ltd | Equity | ₹0.05 Cr | 0.30% |
| Sai Life Sciences Ltd | Equity | ₹0.05 Cr | 0.29% |
| Shilpa Medicare Ltd | Equity | ₹0.05 Cr | 0.29% |
| Alivus Life Sciences Ltd | Equity | ₹0.05 Cr | 0.27% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹0.03 Cr | 0.19% |
| HealthCare Global Enterprises Ltd | Equity | ₹0.03 Cr | 0.18% |
| Blue Jet Healthcare Ltd | Equity | ₹0.03 Cr | 0.17% |
| Emcure Pharmaceuticals Ltd | Equity | ₹0.03 Cr | 0.16% |
| FDC Ltd | Equity | ₹0.03 Cr | 0.16% |
| Supriya Lifescience Ltd | Equity | ₹0.03 Cr | 0.15% |
| Indraprastha Medical Corp Ltd | Equity | ₹0.02 Cr | 0.14% |
| Morepen Laboratories Ltd | Equity | ₹0.02 Cr | 0.14% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.02 Cr | 0.13% |
| Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.02 Cr | 0.13% |
| Sequent Scientific Ltd | Equity | ₹0.02 Cr | 0.12% |
| Hikal Ltd | Equity | ₹0.02 Cr | 0.12% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹0.02 Cr | 0.12% |
| Krsnaa Diagnostics Ltd | Equity | ₹0.02 Cr | 0.11% |
| Unichem Laboratories Ltd | Equity | ₹0.02 Cr | 0.11% |
| Dishman Carbogen Amics Ltd | Equity | ₹0.02 Cr | 0.11% |
| Innova Captab Ltd | Equity | ₹0.02 Cr | 0.11% |
| Advanced Enzyme Technologies Ltd | Equity | ₹0.02 Cr | 0.11% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.10% |
| Aarti Drugs Ltd | Equity | ₹0.02 Cr | 0.10% |
| Orchid Pharma Ltd | Equity | ₹0.02 Cr | 0.10% |
| Thyrocare Technologies Ltd | Equity | ₹0.01 Cr | 0.08% |
| RPG Life Sciences Ltd | Equity | ₹0.01 Cr | 0.08% |
| Gufic Biosciences Ltd | Equity | ₹0.01 Cr | 0.07% |
| Gujarat Themis Biosyn Ltd | Equity | ₹0.01 Cr | 0.07% |
| Indoco Remedies Ltd | Equity | ₹0.01 Cr | 0.07% |
| Windlas Biotech Ltd | Equity | ₹0.01 Cr | 0.07% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.01 Cr | 0.06% |
| Bliss GVS Pharma Ltd | Equity | ₹0.01 Cr | 0.06% |
| Syncom Formulation (India) Ltd | Equity | ₹0.01 Cr | 0.06% |
| Vimta Labs Ltd | Equity | ₹0.01 Cr | 0.06% |
| Suven Life Sciences Ltd | Equity | ₹0.01 Cr | 0.06% |
| IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.06% |
| Sigachi Industries Ltd | Equity | ₹0.01 Cr | 0.05% |
| SMS Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.05% |
| Shalby Ltd | Equity | ₹0.01 Cr | 0.04% |
| Lincoln Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.04% |
| Novartis India Ltd | Equity | ₹0.01 Cr | 0.04% |
| Hester Biosciences Ltd | Equity | ₹0.01 Cr | 0.04% |
| Kopran Ltd | Equity | ₹0.01 Cr | 0.04% |
| Tarsons Products Ltd | Equity | ₹0.01 Cr | 0.04% |
| Senores Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.04% |
| Themis Medicare Ltd | Equity | ₹0.01 Cr | 0.03% |
| GPT Healthcare Ltd | Equity | ₹0.01 Cr | 0.03% |
| Suraksha Diagnostic Ltd | Equity | ₹0 Cr | 0.03% |
| KMC Speciality Hospitals (India) Ltd | Equity | ₹0 Cr | 0.02% |
| Sastasundar Ventures Ltd | Equity | ₹0 Cr | 0.02% |
| NGL Fine-Chem Ltd | Equity | ₹0 Cr | 0.02% |
| Cash Margin - Ccil | Cash - Repurchase Agreement | ₹0 Cr | 0.00% |
Allocation By Market Cap (Equity)
Large Cap Stocks
45.26%
Mid Cap Stocks
27.87%
Small Cap Stocks
26.00%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹17.08 Cr | 98.46% |
| Basic Materials | ₹0.1 Cr | 0.59% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
AJ
Abhishek Jain
Since March 2025
Additional Scheme Detailsas of 31st March 2025
ISIN INF194KB1IR4 | Expense Ratio 1.01% | Exit Load No Charges | Fund Size ₹17 Cr | Age 5 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
|---|---|---|---|---|
| SBI BSE PSU Bank Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹8.42 Cr | - |
| SBI BSE PSU Bank Index Fund Regular Growth Very High Risk | 0.8% | 0.0% | ₹8.42 Cr | - |
| SBI BSE PSU Bank ETF Very High Risk | 0.3% | - | ₹205.39 Cr | - |
| Tata BSE Quality Index Fund Direct Growth Very High Risk | - | 0.0% | - | - |
| Tata BSE Quality Index Fund Regular Growth Very High Risk | - | 0.0% | - | - |
| HDFC Nifty Top 20 Equal Weight Index Fund Direct Growth Very High Risk | - | 0.0% | ₹70.51 Cr | - |
| HDFC Nifty Top 20 Equal Weight Index Fund Regular Growth Very High Risk | - | 0.0% | ₹70.51 Cr | - |
| Kotak Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.3% | 0.0% | ₹7.20 Cr | - |
| Kotak Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹7.20 Cr | - |
| Mirae Asset BSE 200 Equal Weight ETF Very High Risk | - | - | ₹14.21 Cr | - |
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Bandhan BSE Healthcare Index Fund Regular Growth?
The NAV of Bandhan BSE Healthcare Index Fund Regular Growth, as of 17-Apr-2025, is ₹9.55.
What is the portfolio composition of Bandhan BSE Healthcare Index Fund Regular Growth?
The fund's allocation of assets is distributed as 99.89% in equities, 0.00% in bonds, and 0.11% in cash and cash equivalents.
Who manages the Bandhan BSE Healthcare Index Fund Regular Growth?
The fund managers responsible for Bandhan BSE Healthcare Index Fund Regular Growth are:-
- Abhishek Jain
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
Track all you investments in one place
Download Wealth Monitor App
©2021-2025 Dezerv. All Rights Reserved
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Get your portfolio reviewed by experts
